Format

Send to

Choose Destination
BMC Cancer. 2016 Apr 8;16:264. doi: 10.1186/s12885-016-2298-x.

Advance care planning--a multi-centre cluster randomised clinical trial: the research protocol of the ACTION study.

Author information

1
Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands. j.rietjens@erasmusmc.nl.
2
Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
3
International Observatory on the End-of-Life Care, Lancaster University, Lancaster, LA1 4YG, UK.
4
Department of Public Health, University of Copenhagen, Øster Farimagsgade 5, 1014, København, Denmark.
5
University Clinic for Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.
6
Clinical and Descriptive Epidemiology Unit, ISPO Cancer Prevention and Research Institute, Florence, Italy.
7
School of Health Sciences, Sue Ryder Centre for the Study of Supportive, Palliative and End of Life Care, University of Nottingham, Queen's Medical Centre, Nottingham, UK.
8
Julius Center for Health Sciences and Primary Care, Medical School of Utrecht University, Utrecht, The Netherlands.
9
End-of-life Care Research Group, Vrije Universiteit Brussel (VUB) & Ghent University, Brussels, Belgium.
10
Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium.
11
The Research Unit, Department of Palliative Medicine, Bispebjerg / Frederiksberg Hospital, Bispebjerg Bakke 23, 2400, København, NV, Denmark.
12
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
13
Department of Psychology, University of Southern Denmark, Campusvej 55, Odense, 5230, Denmark.
14
School of Medicine, University of Nottingham, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Abstract

BACKGROUND:

Awareness of preferences regarding medical care should be a central component of the care of patients with advanced cancer. Open communication can facilitate this but can occur in an ad hoc or variable manner. Advance care planning (ACP) is a formalized process of communication between patients, relatives and professional caregivers about patients' values and care preferences. It raises awareness of the need to anticipate possible future deterioration of health. ACP has the potential to improve current and future healthcare decision-making, provide patients with a sense of control, and improve their quality of life.

METHODS/DESIGN:

We will study the effects of the ACP program Respecting Choices on the quality of life of patients with advanced lung or colorectal cancer. In a phase III multicenter cluster randomised controlled trial, 22 hospitals in 6 countries will be randomised. In the intervention sites, patients will be offered interviews with a trained facilitator. In the control sites, patients will receive care as usual. In total, 1360 patients will be included. All participating patients will be asked to complete questionnaires at inclusion, and again after 2.5 and 4.5 months. If a patient dies within a year after inclusion, a relative will be asked to complete a questionnaire on end-of-life care. Use of medical care will be assessed by checking medical files. The primary endpoint is patients' quality of life at 2.5 months post-inclusion. Secondary endpoints are the extent to which care as received is aligned with patients' preferences, patients' evaluation of decision-making processes, quality of end-of-life care and cost-effectiveness of the intervention. A complementary qualitative study will be carried out to explore the lived experience of engagement with the Respecting Choices program from the perspectives of patients, their Personal Representatives, healthcare providers and facilitators.

DISCUSSION:

Transferring the concept of ACP from care of the elderly to patients with advanced cancer, who on average are younger and retain their mental capacity for a larger part of their disease trajectory, is an important next step in an era of increased focus on patient centered healthcare and shared decision-making.

TRIAL REGISTRATION:

International Standard Randomised Controlled Trial Number: ISRCTN63110516. Date of registration: 10/3/2014.

KEYWORDS:

Advance care planning; Medical decision-making; Oncology; Quality of life

PMID:
27059593
PMCID:
PMC4826555
DOI:
10.1186/s12885-016-2298-x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center